Liyang Gu

145 Shan Dong Middle Road
Shanghai, 200001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Effects of first-line biologic immunomodulation compared with non-biologic therapies in adult-onset Still's disease: a two-center cohort study.

Effects of first-line biologic immunomodulation compared with non-biologic therapies in adult-onset Still's disease: a two-center cohort study.

Journal: Arthritis research & therapy

Published: May 13, 2026

Distinct immune activation patterns in adult-onset Still's disease with fungal infections.

Distinct immune activation patterns in adult-onset Still's disease with fungal infections.

Journal: Frontiers in immunology

Published: January 29, 2026

Arthroscopic Guided Synovectomy, Synovial Biopsies, and Pathotype Identification in Refractory Rheumatoid Arthritis.

Arthroscopic Guided Synovectomy, Synovial Biopsies, and Pathotype Identification in Refractory Rheumatoid Arthritis.

Journal: Journal of visualized experiments : JoVE

Published: November 24, 2025

Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still's disease/systemic lupus erythematosus: insights from nine cases.

Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still's disease/systemic lupus erythematosus: insights from nine cases.

Journal: Frontiers in immunology

Published: July 31, 2025

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Journal: Med (New York, N.Y.)

Published: May 12, 2025

nCD64 index as a new early predictive biomarker for macrophage activation syndrome in adult-onset still's disease.

nCD64 index as a new early predictive biomarker for macrophage activation syndrome in adult-onset still's disease.

Journal: Arthritis research & therapy

Published: April 25, 2025

Case Report: Spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy.

Case Report: Spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy.

Journal: Frontiers in immunology

Published: February 23, 2025

Integrative PANoptosis gene profiling reveals prognostic and therapeutic insights in prostate cancer.

Integrative PANoptosis gene profiling reveals prognostic and therapeutic insights in prostate cancer.

Journal: Biomolecules & biomedicine

Published: January 06, 2025

Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering.

Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering.

Journal: Frontiers in immunology

Published: December 05, 2023

Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.

Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.

Journal: RMD open

Published: November 14, 2023

Immune profile alterations of systemic lupus erythematosus patients with infections.

Immune profile alterations of systemic lupus erythematosus patients with infections.

Journal: Clinical and experimental medicine

Published: July 13, 2023

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.

Journal: Annals of the rheumatic diseases

Published: October 31, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026